<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01711333</url>
  </required_header>
  <id_info>
    <org_study_id>021-KOA-1102i</org_study_id>
    <nct_id>NCT01711333</nct_id>
  </id_info>
  <brief_title>A Multicenter, Therapeutic Used Study to Evaluate the Efficacy and Safety of Pletaal SR Capsule (Cilostazol) in Subjects With Peripheral Arterial Disease Symptom Due to Chronic Occlusive Arterial Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate symptomatic changes and safety before and after the administration&#xD;
      of Pletaal® SR Capsules based on Peripheral Artery Questionnaire (PAQ) in subjects with&#xD;
      peripheral arterial disease symptom due to chronic occlusive arterial disease (COAD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multinational, single-arm, therapeutic used clinical trial. After screening in&#xD;
      subjects with peripheral arterial disease symptom due to chronic occlusive arterial disease,&#xD;
      the eligible subjects will be enrolled, followed by the administration of the study drug (two&#xD;
      capsules qd of Pletaal SR 100mg Capsules) for 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Summary score based on PAQ (Peripheral artery questionnaire)</measure>
    <time_frame>Change from Baseline in PAQ summary score at Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Score of domain (physical limitation) based on PAQ</measure>
    <time_frame>Change from Baseline in PAQ domain (physical limitation) at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessement based on HAQ-DI</measure>
    <time_frame>Change from Baseline in HAQ-DI at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of domain(symptom) based on PAQ</measure>
    <time_frame>Change from Baseline in PAQ domain(symptom) at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of domain(symptom stability) based on PAQ</measure>
    <time_frame>Change from Baseline in PAQ domain(symptom stability) at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score ofdomain(social limitation) based on PAQ</measure>
    <time_frame>Change from Baseline in PAQ domain (social limitation) at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of domain(treatment satisfaction) based on PAQ</measure>
    <time_frame>Change from Baseline in PAQ domain (treatment satisfaction) at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of domain(quality of life) based on PAQ</measure>
    <time_frame>Change from Baseline in PAQ domain (quality of life) at Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Occlusive Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Pletaal SR capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pletaal SR capsule</intervention_name>
    <description>two capsules once a day of Pletaal SR 100mg Capsules</description>
    <arm_group_label>Pletaal SR capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or Female outpatients between 40 and 75 years of age,&#xD;
&#xD;
          2. Patients confirmed to have symptoms of peripheral arterial disease (including&#xD;
             intermittent claudication, pain, coldness and fatigue) in the lower extremities,&#xD;
&#xD;
          3. Patients who have a steady symptom without significant improvement within 12 weeks&#xD;
             prior to screening visit and whose PAQ score of the question number 3 is 3 or less at&#xD;
             enrollment visit,&#xD;
&#xD;
          4. Ankle Branchial Index (ABI) ≤0.90 when measuring the pressure in a supine position&#xD;
             after resting for 10 minutes,&#xD;
&#xD;
          5. Patients who are equal to or less than 10% of the difference in PAQ summary scores at&#xD;
             between screening and enrollment,&#xD;
&#xD;
          6. Patients who have been fully explained about this study, voluntarily decided to&#xD;
             participate in this study, and provided written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with ischemic pain at rest or having ischemic ulcer or gangrene,&#xD;
&#xD;
          2. Patients with Ankle Branchial Index (ABI) ≤ 0.40&#xD;
&#xD;
          3. Patients who underwent sympathectomy or lower extremity arterial reparative surgery&#xD;
             including endovascular procedures within 12 weeks prior to screening visit,&#xD;
&#xD;
          4. Patients diagnosed of deep vein thrombosis within 12 weeks prior to screening visit,&#xD;
             (provided that patients with isolated calf vein thrombosis may be enrolled)&#xD;
&#xD;
          5. Patients with the following disease:&#xD;
&#xD;
               -  Patients who is on or needs the treatment for Congestive heart failure&#xD;
&#xD;
               -  Myocardial infarction which occurred within 24 weeks prior to screening visit&#xD;
&#xD;
               -  Patients who is on or needs the treatment for unstable angina pectoris,&#xD;
&#xD;
          6. Patients with hemorrhage (hemophilia, capillary fragility, intracranial hemorrhage,&#xD;
             upper gastrointestinal hemorrhage, urinary hemorrhage, hemoptysis, vitreous&#xD;
             hemorrhage, etc.) and predisposition to hemorrhage (active peptic ulcer, hemorrhagic&#xD;
             stroke within the recent 24 weeks, suspected hemorrhage when administering cilostazol&#xD;
             for wound due to surgery within the recent 12 weeks, and proliferative diabetic&#xD;
             retinopathy),&#xD;
&#xD;
          7. PT, aPTT level greater than 1.5 times the upper limit of normal at screening visit,&#xD;
&#xD;
          8. Uncontrolled hypertension defined as ≥ 160 mmHg of systolic blood pressure or ≥ 100&#xD;
             mmHg of diastolic blood pressure,&#xD;
&#xD;
          9. Creatinine clearance(Ccr)a ≤ 25mL/min at screening a. Creatinine clearance (Ccr) is&#xD;
             calculated by the following modified Cockcroft-Gault formula using the serum&#xD;
             creatinine as determined by the site laboratory.&#xD;
&#xD;
        Ccr(mL/min)=[260-age(year)] x Body weight(kg) / 160 x Serum creatinine(mg/dL) (male)&#xD;
        Ccr(mL/min)=[236-age(year)] x Body weight(kg) / 180 x Serum creatinine(mg/dL) (female), 10)&#xD;
        AST or ALT level greater than 3 times the upper limit of normal at screening, 11) Total&#xD;
        bilirubin level greater than 2 times the upper limit of normal at screening, 12) Type 1&#xD;
        diabetes mellitus or uncontrolled type 2 diabetes mellitus (HbA1c greater than 9%), 13)&#xD;
        Patients determined ineligible to participate in this clinical trial at the discretion of&#xD;
        Investigator due to critical diabetic complications (diabetic foot ulcer, foot deformity,&#xD;
        etc.), 14) Female patients whose serum pregnancy test at screening or urine pregnancy test&#xD;
        at enrollment is positive in case of childbearing potential and breastfeeding women,&#xD;
&#xD;
          -  For female patients, those who have been at their postmenopause at least for one year&#xD;
             or longer, who have no potential to be pregnant by surgery or procedure, or who agreed&#xD;
             to use acceptable contraceptive methods (intrauterine device [loop or Mirena], double&#xD;
             barrier method [diaphragm or condom/femidom + spermicide], vasectomy in spouse, oral&#xD;
             contraceptives or non-oral contraceptives) throughout the entire study period,Female&#xD;
             patients whose pregnancy test at screening is positive in case of childbearing&#xD;
             potential or breastfeeding women 15) History of malignant disease (excluding treated&#xD;
             basal cell or squamous cell carcinoma of skin) within 5 years prior to Screening.&#xD;
             Resolution of a prior malignancy more than 5 years prior to Screening must be deemed&#xD;
             as cured by the investigator, 16) Patients who have history of taking or plan to take&#xD;
             the following medications:&#xD;
&#xD;
          -  Cilostazol-containing medications within 12 weeks prior to screening visit,&#xD;
&#xD;
          -  Antiplatelets (such as aspirin and ticlopidine), anticoagulants (such as warfarin),&#xD;
             thrombolytics (such as urokinase and alteplase), prostaglandin E1 and its derivatives&#xD;
             (such as alprostadil and limaprost), pentoxyfylline, beraprost, sarpogrelate and&#xD;
             statin within 4 weeks prior to screening visit. However, aspirin (≤ 100 mg) or statin&#xD;
             being taken for more than 4 weeks prior to screening visit may be administered at the&#xD;
             same dose.&#xD;
&#xD;
          -  Nitrates, papaverine, isoxsuprine, and NSAIDs within 4 weeks prior to screening visit.&#xD;
             However, NSAIDs being taken for more than 4 weeks prior to screening visit may be&#xD;
             administered at the same dose, 17) Patients with a history of hypersensitivity to&#xD;
             cilostazol, 18) Patients who have received an investigational product or biological&#xD;
             agent within 12 weeks prior to screening visit, 19) Patients who plans to enroll in&#xD;
             another clinical trial (excluding observational studies) during this study, 20)&#xD;
             Patients who needs to stop the Investigational Product because of scheduled operation,&#xD;
             extraction of tooth or endoscopy, 21) Patients who are otherwise judged by the&#xD;
             investigator to be inappropriate for inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>KYUNG-HEE UNIVERSITY HOSPITAL at GANGDONG</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Kyu Jeung Ahn, PhD</last_name>
      <phone>822-440-6125</phone>
      <email>ahnkj@khnmc.or.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>October 18, 2012</study_first_submitted>
  <study_first_submitted_qc>October 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2012</study_first_posted>
  <last_update_submitted>October 23, 2012</last_update_submitted>
  <last_update_submitted_qc>October 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

